Core Viewpoint - The article highlights the significant risks associated with medication management among the elderly, emphasizing the need for better support systems to ensure safe medication practices [1][9]. Group 1: Medication Safety Issues - Many elderly individuals have disorganized medicine cabinets filled with expired or inappropriate medications, leading to potential health risks [2][8]. - Instances of medication misuse, such as taking multiple doses or mixing similar medications, are common among the elderly, resulting in dangerous health consequences [3][4]. - The lack of clear labeling and understanding of medication instructions exacerbates the problem, as many elderly individuals struggle with vision and memory issues [5][6]. Group 2: Healthcare Provider Challenges - Healthcare providers face challenges in ensuring elderly patients adhere to medication regimens, often finding that patients forget instructions shortly after receiving them [3][4]. - Community health services attempt to provide regular check-ups and personalized medication advice, but many elderly patients still encounter difficulties in managing their medications effectively [3][4]. - Pharmacists also report difficulties in communicating with elderly patients, who may not accurately describe their medication needs or understand the implications of their choices [5][6]. Group 3: Societal Responsibility - The article calls for a collective effort from community hospitals, pharmacies, and families to improve medication safety for the elderly [9]. - There is a need for clearer guidance and ongoing support to help elderly individuals manage their medications safely, transforming their medicine cabinets from potential health risks into effective health management tools [8][9].

Core Viewpoint - Chengdu Yuandong Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of its drug, Ethyl Pheylbutazone Tablets, marking a significant milestone for the company in the pharmaceutical market [1][2]. Drug Basic Information - Drug Name: Ethyl Pheylbutazone Tablets - Dosage Form: Tablets - Specification: 50mg - Registration Category: Chemical Drug Class 4 - Validity Period: 18 months - Holder of Marketing Authorization: Chengdu Shode Pharmaceutical Co., Ltd. - Production Company: Chengdu Shode Pharmaceutical Co., Ltd. - Registration Standard Number: YBH23792025 - Acceptance Number: CYHS2402415 - Certificate Number: 2025S02973 - Approval Document Number: Guoyao Zhunzi H20255554 - Approval Conclusion: The drug meets the registration requirements as per the relevant laws and regulations [1]. Drug Indications and Market Context - The primary active ingredient is Ethyl Pheylbutazone, indicated for conditions such as cervical, shoulder, and lumbar pain, as well as various spastic paralysis conditions [2]. - The drug was originally developed by Eisai Co., Ltd. in Japan and was first approved for sale in Japan in February 1983, later imported to China in July 2004 [2]. - It is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Directory (2024) [2]. - The drug is the first generic drug approved under the new registration classification, equivalent to passing the consistency evaluation [2]. - Sales data from major public hospitals indicate that the expected sales for Ethyl Pheylbutazone Tablets in 2024 are approximately 102.61 million yuan, reflecting a year-on-year growth of 14.01% [2]. Impact on the Company - The approval of Ethyl Pheylbutazone Tablets signifies that the product meets the necessary registration requirements, although it is not expected to have a significant impact on the company's short-term performance [3]. - The period from approval to market production may face uncertainties, and the company will fulfill its information disclosure obligations as required by law [3].

Core Viewpoint - Chengdu Yuandong Pharmaceutical Co., Ltd. has received the drug registration certificate for its product, Hydrochloride Ephedrine Tablets, marking a significant milestone in its product portfolio and compliance with regulatory standards [1][2]. Drug Basic Information - Drug Name: Hydrochloride Ephedrine Tablets - Dosage Form: Tablets - Specification: 50mg - Registration Category: Class 4 Chemical Drug - Validity Period: 18 months - Holder of Marketing Authorization: Chengdu Shuo De Pharmaceutical Co., Ltd. - Production Company: Chengdu Shuo De Pharmaceutical Co., Ltd. - Drug Registration Standard Number: YBH23792025 - Approval Conclusion: The product meets the requirements for drug registration and has been granted a registration certificate [1][2]. Drug Indications - Hydrochloride Ephedrine Tablets are indicated for: 1. Improving muscle tension in conditions such as cervical shoulder-arm syndrome, periarthritis of the shoulder, and low back pain 2. Spastic paralysis caused by cerebrovascular disorders, spastic myelopathy, cervical spondylosis, postoperative sequelae, traumatic sequelae, amyotrophic lateral sclerosis, infantile cerebral palsy, and other spinal cord diseases [2]. Market Performance - The sales amount for Hydrochloride Ephedrine Tablets in public hospitals in key provinces and cities is projected to be approximately 102.61 million yuan in 2024, reflecting a year-on-year growth of 14.01% [3]. Impact on the Company - The approval of Hydrochloride Ephedrine Tablets signifies that the product meets the necessary registration requirements and is considered to have passed the consistency evaluation. However, it is noted that the approval will not have a significant impact on the company's short-term performance [4].

Core Viewpoint - The company Yuandong Biotech (688513.SH) announced that its wholly-owned subsidiary Chengdu Shode Pharmaceutical Co., Ltd. has received the drug registration certificate from the National Medical Products Administration for its product, Etifoxine Hydrochloride Tablets [1] Group 1: Product Information - The drug Etifoxine Hydrochloride Tablets is primarily indicated for improving muscle tension states associated with conditions such as cervical shoulder-arm syndrome, periarthritis of the shoulder, and low back pain [1] - Additional indications include treatment for spastic paralysis caused by cerebrovascular disorders, spastic myelopathy, cervical spondylosis, postoperative sequelae (including brain and spinal cord tumors), and post-traumatic sequelae (such as spinal cord injury and head trauma) [1] - The drug is also indicated for conditions like amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorders, subacute optic neuritis myelitis (SMON), and other brain and spinal cord diseases that lead to spastic paralysis [1]

Core Viewpoint - Company Yuandong Biotech (688513.SH) has received approval from the National Medical Products Administration for its drug, Ephedrine Hydrochloride Tablets, which is expected to address various medical conditions related to muscle tension and spastic paralysis [1] Group 1: Drug Approval - The company's wholly-owned subsidiary, Chengdu Shode Pharmaceutical Co., Ltd., has been granted a Drug Registration Certificate for Ephedrine Hydrochloride Tablets [1] - The approval signifies a significant milestone for the company in expanding its pharmaceutical portfolio [1] Group 2: Indications and Uses - Ephedrine Hydrochloride Tablets are indicated for improving conditions such as cervical shoulder-arm syndrome, periarthritis of the shoulder, and low back pain related to muscle tension [1] - The drug is also applicable for various neurological and muscular disorders, including cerebrovascular disorders, spastic myelopathy, cervical spondylosis, and post-surgical sequelae [1]

Core Viewpoint - Yuan Dong Biotech (688513) announced the approval of its subsidiary Chengdu Shuo De Pharmaceutical's drug registration certificate for Ephedrine Hydrochloride Tablets by the National Medical Products Administration [1] Group 1 - The active ingredient of Ephedrine Hydrochloride Tablets is Ephedrine Hydrochloride [1] - The primary indications for the drug include improvement of muscle tension conditions related to cervical shoulder-arm syndrome, periarthritis of the shoulder, low back pain, cerebrovascular disorders, spastic myelopathy, cervical spondylosis, and postoperative sequelae [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) announced that its wholly-owned subsidiary Chengdu Shuo De Pharmaceutical Co., Ltd. has received the Drug Registration Certificate approved by the National Medical Products Administration for its product, Ephedrine Hydrochloride Tablets [1] Group 1: Company Developments - Chengdu Shuo De Pharmaceutical has been granted approval for Ephedrine Hydrochloride Tablets, which is a significant milestone for the company [1] - The active ingredient of the tablets is Ephedrine Hydrochloride, indicating the company's focus on addressing various medical conditions [1] Group 2: Product Indications - The primary indications for Ephedrine Hydrochloride Tablets include improving muscle tension states in conditions such as cervical shoulder-arm syndrome, periarthritis of the shoulder, and low back pain [1] - The product is also indicated for spastic paralysis caused by cerebrovascular disorders, spastic myelitis, cervical spondylosis, postoperative sequelae, and other neurological conditions [1]

Core Viewpoint - Yuan Dong Biotech (688513.SH) announced that its wholly-owned subsidiary, Shuo De Pharmaceutical, has received the drug registration certificate from the National Medical Products Administration for the drug Etifoxine Hydrochloride Tablets, which is expected to generate approximately 103 million yuan in sales in 2024, reflecting a year-on-year growth of 14.01% [1] Company Summary - The drug Etifoxine Hydrochloride Tablets, with a specification of 50mg, is classified as a Class 4 chemical drug and is indicated for improving muscle tension states associated with conditions such as cervical spondylosis, shoulder periarthritis, and low back pain [1] - The drug was originally developed by Japan's Eisai Co., Ltd. and was first approved for sale in Japan in 1983 [1] - The approval of this drug is considered equivalent to passing the consistency evaluation, and it is not expected to have a significant impact on the company's recent performance [1] Industry Summary - The projected sales figure of approximately 103 million yuan for 2024 indicates a positive growth trajectory for the drug within the market, suggesting a healthy demand for treatments addressing muscle tension related to common musculoskeletal disorders [1]